2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
3
Recurrence
2
Pancreatic Neoplasms
2
Lymphoma, B-Cell
2
Liver Neoplasms
2
Hematologic Neoplasms
2
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Metastatic Solid Tumors
1
Mesothelioma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Hemorrhage
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Gynecological Solid Tumors
1
Fallopian Tube Neoplasms
1
Erectile Dysfunction
1
Diarrhea
1
Colitis
1
Childhood Solid Tumor
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
222
lenvatinib
147
Bevacizumab
131
Nivolumab
87
atezolizumab
81
pembrolizumab
74
Radiosurgery
71
durvalumab
63
sintilimab
61
Oxaliplatin
60
Fluorouracil
56
Doxorubicin
47
tislelizumab
46
apatinib
45
Radiofrequency Ablation
44
Hepatectomy
43
camrelizumab
41
Leucovorin
41
Radiotherapy
40
tremelimumab
37
Magnetic Resonance Spectroscopy
36
regorafenib
34
Capecitabine
30
Immune Checkpoint Inhibitors
29
Folfox protocol
29
Cisplatin
28
cabozantinib
26
Gemcitabine
26
Cyclophosphamide
26
Ipilimumab
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Cell- and Tissue-Based Therapy
×
Clear all
NCT06084884
2026-05-22
ATHENA
AstraZeneca
Phase 1/2
Active not recruiting
94 enrolled